459
Views
2
CrossRef citations to date
0
Altmetric
Commentary

Localization of death receptor 4 in lipid rafts sensitizes chronic lymphocytic leukemia to chemotherapeutic drug mediated apoptosis

&
Pages 1176-1177 | Published online: 04 Apr 2011

References

  • Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer. CA Cancer J Clin. 2005;55:178–194.
  • Kuafman SH, Hengartner MO. Programmed cell death: alive and well in the new millennium. Trends Cell Biol 2001;11: 526–534.
  • Reed JC. Apoptosis-based therapies. Nat Rev Drug Discov 2002;1:111–121.
  • Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770–776.
  • Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305–1308.
  • Henson ES, Johnston JB, Gibson SB. The role of TRAIL death receptors in the treatment of hematological malignancies. Leuk Lymphoma 2008;49:27–35.
  • Spierings DC, de Vries EG, Vellenga E, Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem 2004;52:821–831.
  • Suliman A, Lam A, Datta R, Srivastava RK. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Oncogene 2001;20: 2122–2133.
  • Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, Peter ME. Apoptosis signaling by death receptors. Eur J Biochem 1998;254:439–459.
  • Johnston JB, Kabore AF, Strutinsky J, Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia. Oncogene 2003;22:8356–8369.
  • Hussain AR, Ahmed M, Al-Jomah NA, Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol Cancer Ther 2008;7: 3318–3329.
  • Xiao W, Ishdorj G, Sun J, Johnston JB, Gibson SB. Death receptor 4 is preferentially recruited to lipid rafts in chronic lymphocytic leukemia cells contributing to tumor necrosis factor related apoptosis inducing ligand-induced synergistic apoptotic responses. Leuk Lymphoma 2011;52: 1290–1301.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.